FDA approves twice-a-year injection for HIV prevention

The FDA has approved Gilead Sciences' lenacapavir, to be marketed as Yeztugo, as a twice-yearly injectable for HIV prevention, demonstrating up to 100% efficacy in clinical trials. This new PrEP option offers a less frequent dosing schedule compared to existing daily pills or bi-monthly injections, potentially improving adherence and addressing stigma, according to Gilead. While the list price for lenacapavir as PrEP is yet to be announced, its approval arrives amidst concerns over proposed budget cuts to HIV prevention programs.

Analysis

Gilead Sciences (GILD) has secured FDA approval for lenacapavir, to be marketed as Yeztugo, a twice-yearly injectable for HIV pre-exposure prophylaxis (PrEP). This approval signifies a substantial advancement in HIV prevention, introducing the first PrEP option with a biannual dosing regimen, which offers a notable convenience advantage over existing daily oral medications, such as Gilead's own Truvada, and bi-monthly injections like GSK's Apretude. Clinical trial data, including the PURPOSE 2 trial which showed a 96% reduction in HIV infection risk (and in one analysis, only two infections among 2,180 participants, making it 89% more effective than Truvada) and the PURPOSE 1 trial demonstrating 100% efficacy in women, highlight Yeztugo's robust efficacy. This less frequent administration is anticipated to improve patient adherence and mitigate stigma, potentially broadening PrEP uptake significantly. Gilead has stated that patients may be able to inquire about the drug within days, though access could take up to two months depending on insurance coverage. The list price for Yeztugo as a preventative treatment is yet to be announced but will differ from its existing price for multidrug-resistant HIV treatment (around $45,000 annually). An independent academic study indicated that lenacapavir could potentially be mass-produced for under $100 per person per year, contingent on factors like voluntary licensing and generic competition, although this is distinct from Gilead's immediate pricing strategy. The drug was generally well-tolerated, with injection-site reactions being the most common side effects. This positive development for Gilead, reflected in a strongly positive sentiment score (0.85 for GILD), occurs against a backdrop of potential US federal budget cuts to HIV prevention programs, which could influence the broader market landscape.

Key Decisions for Investors

• For Gilead (GILD) investors, this FDA approval represents a significant growth catalyst and a strengthening of its HIV franchise; however, the forthcoming announcement of Yeztugo's pricing for PrEP will be crucial in determining its market penetration and revenue potential, especially against established competitors.
• Investors should closely monitor Yeztugo's market adoption rates, paying attention to how its twice-yearly dosing schedule affects patient and physician preferences compared to daily oral PrEP and GSK's bi-monthly injectable Apretude, as this will indicate its disruptive potential.
• The proposed cuts to US government funding for HIV prevention programs present a potential headwind; investors should assess how these fiscal changes might impact the overall PrEP market size and accessibility, which could temper Yeztugo's uptake despite its clinical advantages.